Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Oral Vinorelbine|DRUG: Letrozole
Sponsor: SOLTI Breast Cancer Research Group
Collaborators: Pierre Fabre Laboratories